| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H13N5OS |
| Molecular Weight | 311.362 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(NCC1=CC=CC=C1)C2=CSC(NC3=NC=NC=C3)=N2
InChI
InChIKey=DOBKQCZBPPCLEG-UHFFFAOYSA-N
InChI=1S/C15H13N5OS/c21-14(17-8-11-4-2-1-3-5-11)12-9-22-15(19-12)20-13-6-7-16-10-18-13/h1-7,9-10H,8H2,(H,17,21)(H,16,18,19,20)
| Molecular Formula | C15H13N5OS |
| Molecular Weight | 311.362 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Thiazovivin is a novel ROCK (Rho-associated kinase) inhibitor and Rho-ROCK axis regulates cell-ECM and cell-cell adhesion. Recently was shown, that thiazovivin was effective for protecting the morphology and function of human corneal endothelial cells (HCECs). An optimal improvement in the morphology, connection and function of HCECs was found when the primary HCECs were cultured with thiazovivin.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|